Wanbury Ltd - 524212 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Wanbury's promoter group released pledge on 40.65% of the company's paid-up capital, making 94.51% of their holding unencumbered. This refinancing also reduces the company's borrowing cost to below 10% p.a. from July 1, 2026, boosting profitability.
Jun 25 2026 13:47:45
Wanbury Ltd - 524212 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Wanbury announced expanded regulatory submissions for new Active Pharmaceutical Ingredients (APIs), including Diphenhydramine HCl for Malaysia/Singapore and Paroxetine HCl for Korea/Latin America. The company also received a positive zero-observation audit report from Korea FDA for its Patalganga facility.
Jun 09 2026 13:31:14
Wanbury Ltd - 524212 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Wanbury has scheduled an investor and analyst group meeting combined with a physical plant visit on June 5, 2026. The discussion will cover past financial results and information already available in the public domain.
Jun 02 2026 18:39:12
Wanbury Ltd - 524212 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Wanbury Ltd. delivered strong FY26 audited financial results. Net profit surged 117% YoY to Rs.66.1 crore, while revenue increased by 8.5% to Rs.650.3 crore, driven by new API launches and operational efficiencies.
Jun 02 2026 12:22:09
Wanbury Ltd - 524212 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 29.05.2026
Wanbury's board approved Q4 and FY26 audited financial results. Full-year revenue rose 8.46% to ₹650.27 crore, with net profit surging 116.6% to ₹66.13 crore. Auditors provided an unmodified opinion.
May 29 2026 20:52:04
Read More